In short. What regulators have published about unapproved exosome and birth tissue injections, what a warning does and does not establish, and why silence is not approval.
Key points
- A safety communication reports that an assessment was never done and that harm has been reported.
- It does not establish that a specific product caused a specific injury, and it does not mean every person injected was harmed.
- Both of those things are true at once, and holding them together is more accurate than choosing one.
Regulators in several countries have published safety communications about products marketed as exosomes, and about products derived from birth tissue, when those products are injected. The communications differ in wording and in the detail of national law. They agree on the substance, and the substance is short.
What the communications say
The consistent points are these. No product of this kind has been approved for injection for cosmetic purposes. Marketing one for injection is not permitted where the communications apply. Serious adverse events have been reported in people who received such injections, including infections that needed hospital treatment. And where a person is considering an unapproved injectable, the advice is to use a product that has been through an approval process instead.
Those four points carry different weights, and separating them matters. The first two are statements about legal status. The third is a statement about reported harm. The fourth is advice, which a reader is free to weigh rather than obey.
What a warning is, and what it is not
A warning of this kind is not a finding that a particular product caused a particular injury. It is a statement that the premarket assessment which would normally establish safety and effectiveness was never carried out, and that the regulator has seen enough reports to say so publicly.
A warning is not a verdict on each case
A safety communication reports that an assessment was never done and that harm has been reported. It does not establish that a specific product caused a specific injury, and it does not mean every person injected was harmed. Both of those things are true at once, and holding them together is more accurate than choosing one.
Regulatory status differs by country
There is no single worldwide position. Some regulators have issued explicit statements that these products are not approved for injection. Some have acted against particular sellers. Others have published little, which reflects the limits of a remit or of resources rather than a judgement that the products are acceptable. In most markets there is no approval for such a product to hold, so an approved status cannot travel from one country into another.
The practical point that follows is easy to get wrong. Absence of enforcement is not approval. A clinic operating openly in a country where no action has been taken is not operating with permission in any positive sense; it is operating where nobody has yet intervened, which is a different statement and a much weaker one.
Three ways a regulatory position gets misreported
- An unregulated market described as an approving one, when no approval exists anywhere.
- A warning about a whole category presented as a finding about the individual patient in front of you.
- A position in one country quoted as though it settled the question everywhere.
What regulators have said is narrower than either the sellers or the alarm suggests, and it is more useful than both: the assessment was never done.
Frequently asked questions
Which regulators have published statements about exosome injections?
Several national regulators have issued safety communications about products marketed as exosomes, and about products derived from birth tissue, when those products are injected. They differ in wording and in the detail of national law. They agree on the substance, and some have gone further and taken action against particular sellers.
Does a safety warning mean a particular product caused harm?
Not in the way a court finding would. A communication of this kind reports that the premarket assessment which would normally establish safety and effectiveness was never carried out, and that adverse events including serious infections have been reported. It does not establish that a specific product caused a specific injury in a specific person, and it does not mean everyone injected was harmed.
If a clinic operates openly, does that mean the product is permitted?
No. In most markets there is no approval for an exosome injectable to hold, so a product cannot carry an approved status from one country into another. A clinic operating where no action has yet been taken is not operating with permission in any positive sense. Absence of enforcement is not approval, and the two are routinely presented as though they were the same.
Risks & Limitations
- No product marketed as an exosome injectable has been through the approval process that would establish what it contains or what it does.
- Birth tissue derived material carries an infection risk when it is injected, and serious infections have been reported after such injections.
- The evidence behind most claims comes from laboratory work, animal models or uncontrolled case series, none of which establishes an effect in people.
- Regulatory status differs by country, and in most markets there is no approval for these products in any injectable use.
- Nothing on this site is a recommendation for or against any treatment, and it does not assess individual cases.
When to Seek Care
- Spreading redness, heat, swelling or discharge at an injection site: have it assessed promptly.
- Fever, or feeling unwell with a painful injected area: seek medical care without waiting.
- Severe or worsening pain, blistering, or skin breakdown where something was injected.
- Any new and persistent symptom after a treatment: have it assessed by a clinician who can examine you.
References & Further Reading
- American Society of Plastic Surgeons (ASPS) — procedure and safety guidance
- National Institute for Health and Care Excellence (NICE, UK) — relevant guidance
- Cochrane Library — systematic reviews
- Chinese Medical Association Plastic Surgery Branch — clinical guidance
This page is patient education, not medical advice, and it does not cite individual studies. It reviews evidence and regulation; it is not a booking page and does not recommend a treatment. Discuss your own case with a qualified clinician. To ask a question about this review, see Contact & Consultation.